OncoMatch/Clinical Trials/NCT04920032
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Is NCT04920032 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including TAS-102 and Irinotecan for colon adenocarcinoma.
Treatment: TAS-102 · Irinotecan · Standard Treatment — This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: perioperative chemotherapy — perioperative
after at least 3 months of perioperative chemotherapy
Cannot have received: TAS-102 (TAS-102)
Prior treatment with TAS-102 at any time
Cannot have received: irinotecan (irinotecan)
irinotecan within 90 days from enrollment
Lab requirements
Blood counts
leukocytes ≥ 3,000/mcL; absolute neutrophil count: ≥ 1,500/mcL; platelets: ≥ 80,000/mcl
Kidney function
creatinine: <1.5 X ULN
Liver function
total bilirubin: within normal institutional limits; AST(SGOT)/ALT(SPGT): ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present
Adequate organ and marrow function as defined below: 1. leukocytes ≥ 3,000/mcL 2. absolute neutrophil count: ≥ 1,500/mcL 3. platelets: ≥ 80,000/mcl 4. total bilirubin: within normal institutional limits 5. AST(SGOT)/ALT(SPGT): ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present 6. creatinine: <1.5 X ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California, Irvine · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify